Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
Lara A DunnMatthew G FuryEric J ShermanAlan A HoNora KatabiSofia S HaqueDavid G PfisterPublished in: Head & neck (2017)
Afatinib, ribavirin, paclitaxel, and carboplatin induction chemotherapy is safe and well tolerated. The phase II recommended dose of afatinib is 40 mg oral daily in this combination regimen.
Keyphrases
- squamous cell
- phase ii
- epidermal growth factor receptor
- phase ii study
- phase iii
- clinical trial
- open label
- locally advanced
- advanced non small cell lung cancer
- chemotherapy induced
- papillary thyroid
- physical activity
- squamous cell carcinoma
- radiation therapy
- double blind
- placebo controlled
- tyrosine kinase
- rectal cancer
- study protocol
- lymph node metastasis